Abstract
Systemic vascular resistance (SVR) refers to the resistance of the blood vessels to the blood flow in the circulatory system. Pathologies that cause damage to the blood vessel walls can have an impact on SVR, and common conditions that can disrupt normal SVR include diabetes mellitus and hypertension.
Psoriasis is considered as chronic-recurrent, systemic inflammatory disease, driven by an intense cross talk between cells of the innate and adaptive immune system. It is associated with substantial cardiovascular (CV) comorbidity. Patients with psoriasis are up to 50% more likely to develop CV disease, and this CV risk increases with skin severity. Among factors influencing CV risk in psoriasis are arterial hypertension, obesity, insulin resistance, hyperlipidaemia and smoking.
Some studies have suggested a potential association between psoriasis and increased systemic vascular resistance. The underlying inflammation and immune dysregulation seen in psoriasis can lead to changes in the blood vessels' structure and function, resulting in increased resistance to blood flow.
However, it's essential to note that the relationship between psoriasis and systemic vascular resistance is still an area of ongoing research. Further research is needed to elucidate the underlying mechanisms in relation to cardiovascular and immune system dysfunction.
We measured cardiovascular parameters: heart rate, systolic and diastolic pressure, cardiac output, and vascular resistance by a Finapres (FINAPRES Medical Systems, The Netherlands) for moderate/severe psoriasis patients. The Finapres is a non-invasive device which continuously measures the arterial blood pressure in a finger and produces a real-time display of the arterial pressure wave.
References:
1.Boehncke WH. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol. 2018 Apr 5;9:579. doi: 10.3389/fimmu.2018.00579. PMID: 29675020; PMCID: PMC5895645.
Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular Risk in Patients with Psoriasis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021 Apr 6;77(13):1670-1680. doi: 10.1016/j.jacc.2021.02.009. PMID: 33795041; PMCID: PMC8168628.
Psoriasis is considered as chronic-recurrent, systemic inflammatory disease, driven by an intense cross talk between cells of the innate and adaptive immune system. It is associated with substantial cardiovascular (CV) comorbidity. Patients with psoriasis are up to 50% more likely to develop CV disease, and this CV risk increases with skin severity. Among factors influencing CV risk in psoriasis are arterial hypertension, obesity, insulin resistance, hyperlipidaemia and smoking.
Some studies have suggested a potential association between psoriasis and increased systemic vascular resistance. The underlying inflammation and immune dysregulation seen in psoriasis can lead to changes in the blood vessels' structure and function, resulting in increased resistance to blood flow.
However, it's essential to note that the relationship between psoriasis and systemic vascular resistance is still an area of ongoing research. Further research is needed to elucidate the underlying mechanisms in relation to cardiovascular and immune system dysfunction.
We measured cardiovascular parameters: heart rate, systolic and diastolic pressure, cardiac output, and vascular resistance by a Finapres (FINAPRES Medical Systems, The Netherlands) for moderate/severe psoriasis patients. The Finapres is a non-invasive device which continuously measures the arterial blood pressure in a finger and produces a real-time display of the arterial pressure wave.
References:
1.Boehncke WH. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol. 2018 Apr 5;9:579. doi: 10.3389/fimmu.2018.00579. PMID: 29675020; PMCID: PMC5895645.
Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular Risk in Patients with Psoriasis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021 Apr 6;77(13):1670-1680. doi: 10.1016/j.jacc.2021.02.009. PMID: 33795041; PMCID: PMC8168628.
Original language | English |
---|---|
Pages | 26-26 |
Number of pages | 1 |
Publication status | Published - 14 Sept 2023 |
Event | 19th Congress of the Baltic Association of Dermatovenerologists (BADV): Healthy Skin and Happy Patient! - LU, Riga, Latvia Duration: 14 Sept 2023 → 16 Sept 2023 Conference number: 19 https://badv2023riga.org/ |
Congress
Congress | 19th Congress of the Baltic Association of Dermatovenerologists (BADV) |
---|---|
Abbreviated title | BADV |
Country/Territory | Latvia |
City | Riga |
Period | 14/09/23 → 16/09/23 |
Internet address |
Keywords*
- Systemic Vascular Resistance
- Psoriasis
Field of Science*
- 3.2 Clinical medicine
Publication Type*
- 3.4. Other publications in conference proceedings (including local)